Comparing Cellectar Biosciences (NASDAQ:CLRB) and Cyclacel Pharmaceuticals (NASDAQ:CYCC)

Cellectar Biosciences (NASDAQ:CLRB) and Cyclacel Pharmaceuticals (NASDAQ:CYCC) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends and earnings.

Institutional and Insider Ownership

16.4% of Cellectar Biosciences shares are owned by institutional investors. Comparatively, 23.6% of Cyclacel Pharmaceuticals shares are owned by institutional investors. 3.7% of Cellectar Biosciences shares are owned by company insiders. Comparatively, 24.0% of Cyclacel Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Cellectar Biosciences and Cyclacel Pharmaceuticals”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cellectar Biosciences	N/A	N/A	-$42.77 million	($1.33)	-0.22
Cyclacel Pharmaceuticals	$74,000.00	22.85	-$22.56 million	($9.40)	-0.03

Cyclacel Pharmaceuticals has higher revenue and earnings than Cellectar Biosciences. Cellectar Biosciences is trading at a lower price-to-earnings ratio than Cyclacel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Cellectar Biosciences has a beta of 0.96, suggesting that its stock price is 4% less volatile than the S&P 500. Comparatively, Cyclacel Pharmaceuticals has a beta of 0.28, suggesting that its stock price is 72% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Cellectar Biosciences and Cyclacel Pharmaceuticals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cellectar Biosciences	0	1	1	0	2.50
Cyclacel Pharmaceuticals	0	1	1	0	2.50

Cellectar Biosciences presently has a consensus target price of $12.50, suggesting a potential upside of 4,180.82%. Cyclacel Pharmaceuticals has a consensus target price of $11.00, suggesting a potential upside of 3,989.22%. Given Cellectar Biosciences’ higher possible upside, research analysts clearly believe Cellectar Biosciences is more favorable than Cyclacel Pharmaceuticals.

Profitability

This table compares Cellectar Biosciences and Cyclacel Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cellectar Biosciences	N/A	N/A	-191.22%
Cyclacel Pharmaceuticals	-18,150.00%	-1,901.11%	-188.23%

Summary

Cyclacel Pharmaceuticals beats Cellectar Biosciences on 6 of the 11 factors compared between the two stocks.

About Cellectar Biosciences

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.

About Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.